- Ironwood Pharmaceuticals (IRWD, Financial) reaffirms full-year 2025 guidance for LINZESS U.S. net sales at $800-$850 million.
- Adjusted EBITDA guidance for 2025 has been raised to over $105 million.
- LINZESS prescription demand grew by 8% year-over-year in Q1 2025.
Ironwood Pharmaceuticals, Inc. (IRWD), a biotechnology company focused on gastrointestinal and rare diseases, confirmed its 2025 guidance for LINZESS U.S. net sales at $800-$850 million and total revenue at $260-$290 million. The company also increased its adjusted EBITDA guidance to more than $105 million for the year.
In the first quarter of 2025, LINZESS prescription demand increased by 8% compared to the same quarter in 2024. However, LINZESS U.S. net sales for Q1 2025 amounted to $138.5 million, representing a 46% decrease from Q1 2024, largely due to changes in AbbVie's estimate of gross-to-net rebate reserves.
Ironwood and its U.S. partner, AbbVie, are addressing anticipated pricing challenges, including those associated with the Medicare Part D redesign. Despite these hurdles, Ironwood remains confident in achieving its full-year financial targets. Additionally, the company is shifting its focus toward a confirmatory Phase 3 trial for apraglutide, following recent feedback from the FDA.
